Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research & Development In Brief

This article was originally published in The Tan Sheet

Executive Summary

No link between multivitamins and cancer reduction: Results from one of the largest diet and health studies show multivitamins did not lower the risk of common cancers or impact heart disease in 161,808 post-menopausal women regularly evaluated for eight years, according to study in the Feb. 9 Archives of Internal Medicine. Researchers led by Marian Neuhouser, an associate at the Public Health Sciences Division of the Fred Hutchinson Cancer Research Center in Seattle, found similar rates of breast, colorectal, endometrial, kidney, bladder, stomach, lung and ovarian cancer in women who took multivitamins and those who did not. Multivitamins were used by about 41 percent of the women Neuhouser's team evaluated, all participants in the Women's Health Initiative clinical trial. The Council for Responsible Nutrition acknowledges multivitamins "are not intended to be magic bullets that will assure the prevention of chronic diseases, like cancer." However, CRN says in a statement that as the study notes, "people who use multivitamins are likely to be healthier and engage in many health habits.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel